Biogen Idec 4Q Revenues: $1.3 billion (+9%) 4Q Earnings: $300.2 million (+10%) FY Revenues: $5.0 billion (+7%) FY Earnings: $1.3 billion (+41%) Comments: Tysabri revenues increased 11% in the quarter to $269 million. Global in-market sales were $380 million, up 14%. Avonex revenues were up 8% in the quarter to $703 million. Rituxan revenues from the company’s joint business arrangement were flat at $258 million in the quarter. For the year Tysabri revenues were up 20% to $1.1 billion with g...